Tandem Labs, ABR Expand Offerings

Tandem Labs and Advanced Biomedical Research, Inc. (ABR) have entered into a formal agreement to expand the service offerings of both organizations. Under the agreement, the two companies will implement a streamlined process maximizing the specialties of both organizations for clients that wish to reduce contract vendor communications and site maintenance responsibilities.

The combined resources of Tandem Labs and ABR include: clinical and bioanalytical services from IND through NDA; new therapeutic entities, from Phase I – IV.

“Tandem Labs is one of the most innovative laboratories in the U.S.,” commented Dr. Michael S. Willett, president and chief executive officer of ABR. “Adding high caliber bioanalytical services to ABR’s current offerings of clinical research, study monitoring, data management, statistical analyses, and medical writing will enable us to more fully meet the complete spectrum of our clients’ needs.”

Dr. Denis Lin, president and chief executive officer of Tandem Labs, added, “This agreement with ABR signifies a critical milestone in our strategy to partner with like-minded organizations with similar corporate missions in our effort to provide clients with the most superior pharmaceutical services available in the market today.”